...
首页> 外文期刊>Annals of oncology: official journal of the European Society for Medical Oncology >A prognostic scoring system based on clinical features of intrahepatic cholangiocarcinoma: the Fudan score.
【24h】

A prognostic scoring system based on clinical features of intrahepatic cholangiocarcinoma: the Fudan score.

机译:基于肝内胆管癌临床特征的预后评分系统:复旦评分。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: The objectives of this study were to propose a clinical prognostic scoring system applicable for intrahepatic cholangiocarcinoma (ICC) and to evaluate the prognostic validity of the American Joint Committee on Cancer (AJCC) 7th edition staging system. PATIENTS AND METHODS: Retrospective univariate and multivariate survival analyses were conducted for 344 patients with ICC who underwent hepatectomy. A simple clinical prognostic scoring system (Fudan score) was developed based on the independent predictors. The prognostic validity was assessed in 74 patients with unresected tumors and compared with the AJCC 6th and 7th edition systems. RESULTS: In the training set, serum alkaline phosphatase level, carbohydrate antigen 19-9 level, tumor boundary type, tumor size, and number of intrahepatic tumors were independent predictive factors of survival in ICC and were incorporated into the Fudan score. Three hundred forty-four patients were categorized into four subsets with 5-year overall survival rates of 48.6%, 25.6%, 10.3%, and 0.0% for low-, intermediate-, high-, and extremely high-risk groups, respectively. The discriminative ability of the Fudan score was better than that of the AJCC staging system and well applied in the unresected patient set. CONCLUSIONS: A Fudan score based on clinical factors may provide a relatively accurate prognostic prediction for ICC patients regardless of resection status.
机译:背景:本研究的目的是提出一种适用于肝内胆管癌(ICC)的临床预后评分系统,并评估美国癌症联合委员会(AJCC)第七版分期系统的预后有效性。患者和方法:对344例接受肝切除的ICC患者进行了回顾性单因素和多因素生存分析。基于独立的预测因素,开发了一个简单的临床预后评分系统(复旦评分)。评估了74例未切除肿瘤的患者的预后有效性,并与AJCC第6版和第7版系统进行了比较。结果:在训练组中,血清碱性磷酸酶水平,糖类抗原19-9水平,肿瘤边界类型,肿瘤大小和肝内肿瘤数目是ICC生存的独立预测因素,并纳入复旦评分。 344例患者分为四类,低,中,高和极高风险组的5年总生存率分别为48.6%,25.6%,10.3%和0.0%。复旦评分的判别能力优于AJCC分期系统,可很好地应用于未切除的患者。结论:基于临床因素的复旦评分可以为ICC患者提供相对准确的预后预测,而与切除状态无关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号